Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Drug metabolite identification and synthesis service

Unique collaboration between Onyx Scientific, Cyprotex and Glytech.

Onyx Scientific Ltd, Cyprotex Discovery Ltd and Glytech, a University of York Centre for Novel Agricultural Products' spin-out, have formed a unique 3-way collaboration to offer drug metabolite identification and synthesis services to the pharmaceutical industry.

All 3 organisations contribute separate skills needed in performing this service. Onyx provides synthetic and analytical chemistry services; Cyprotex contributes in vitro screening services, metabolite profiling and identification expertise; Glytech supplies proprietary enzyme screening and bioprocessing skills providing the capability to rapidly make novel metabolite structures.

No single entity in the world is capable of matching this novel approach.

Most drug substances are converted by the body into compounds that are more easily removed (excreted). By understanding what happens to a new drug, it's structure can be optimised for effect and ultimately further advances can be made in combating disease and alleviating suffering.

Key to early evaluation of new drug substances is an understanding of what is expected to happen to the molecule itself in vivo (in humans). Understanding which metabolites are likely to be formed is essential for interpreting pharmacological, pharmacokinetic and toxicology data. Furthermore, the US Food and Drug Administration (FDA) Guidance for Industry on Safety Testing of Drug Metabolites (2008) recommends the identification of differences in drug metabolism between animals used in preclinical safety assessment with humans as early as possible in the drug development process.

The joint service is being managed and coordinated by Sunderland based Onyx Scientific Ltd.

"We hope this novel collaborative approach will bring in separate business for all 3 organisations and in doing so help streamline and shorten the drug development process and benefit all" said Dr Tony Flinn, Chief Executive Officer at Onyx Scientific Ltd.

For further information:
Onyx Scientific Ltd

Dr Tony Flinn, CEO
Tel: +44 (0)191 516 6516
tonyflinn@onyx-scientific.com
www.onyx-scientific.com

For further information:
Glytech

Professor Dianna Bowles
djb32@york.ac.uk
www.cnap.org.uk.

For further information:
Cyprotex PLC

Helen Gill PhD, Product Development Manager
Tel: +44 (0)1625 505 100
h.gill@cyprotex.com
www.cyprotex.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close